First Heartland Consultants, Inc. Seelos Therapeutics, Inc. Transaction History

First Heartland Consultants, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 17, 2023	SELL	$0.59 - $1.04 $649 - $1,144	-1,100 Reduced 3.63%	29,190 $20,000
Q4 2022 Jan 13, 2023	BUY	$0.66 - $259.46 $66 - $25,945	100 Added 0.33%	30,290 $0
Q2 2022 Jul 12, 2022	BUY	$0.51 - $0.93 $510 - $930	1,000 Added 3.43%	30,190 $20,000
Q1 2022 Apr 21, 2022	BUY	$0.84 - $1.71 $12,600 - $25,650	15,000 Added 105.71%	29,190 $24,000
Q4 2021 Feb 11, 2022	BUY	$1.59 - $2.38 $2,865 - $4,288	1,802 Added 14.55%	14,190 $23,000
Q3 2021 Nov 15, 2021	BUY	$1.69 - $2.89 $1,711 - $2,927	1,013 Added 8.91%	12,388 $30,000
Q2 2021 Aug 16, 2021	BUY	$2.64 - $6.32 $30,030 - $71,890	11,375 New	11,375 $30,000

40.5K

Ticker SEEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 106,691,000
Market Cap $38.4M
Description
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in...

Get notified when there are updates to the investment portfolio of First Heartland Consultants, Inc., based on Form 13F filings with the SEC.

Stay updated on First Heartland Consultants, Inc. with notifications on news.